title: Etoposide in remission induction of adult acute myeloid leukemia.
abstract: 96 consecutive acute myelogenous leukemia (AML) patients were analyzed retrospectively with regard to the regimen used for remission induction. 35 patients received daunorubicin for 3 days, cytosine arabinoside and 6-thioguanine for 7 days. 61 were treated with the same regimen but 6-thioguanine was replaced by etoposide. Complete remission was achieved in 57 and 72% of patients, respectively (p = 0.06). In leukemias with monocytic phenotype (M4-M5), the remission rate was significantly higher with the etoposide-containing regimen (p = 0.02). Our findings suggest that the replacement of thioguanine by etoposide could be useful in induction therapy of AML.
authors.affiliation: Divisione Ematologia USL 10/D, Università degli Studi, Policlinico di Careggi, Firenze, Italia.
authors.forename: F
authors.initials: F
authors.lastname: Leoni
authors.forename: S
authors.initials: S
authors.lastname: Ciolli
authors.forename: S
authors.initials: S
authors.lastname: Patriarchi
authors.forename: M
authors.initials: M
authors.lastname: Morfini
authors.forename: P
authors.initials: P
authors.lastname: Rossi Ferrini
mesh_terms: D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D012189:Retrospective Studies; D013866:Thioguanine / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D003561:Cytarabine; D005047:Etoposide; D013866:Thioguanine; D003630:Daunorubicin